This legislation, titled the "Drug Deal Disclosure Act," requires the Secretary of Health and Human Services to make publicly available all records, documents, and communications concerning drug pricing agreements between federal agencies and pharmaceutical manufacturers. This disclosure must occur within 30 days of the bill's enactment for existing agreements and within 30 days of ratification for any new or modified agreements. The information is to be presented in a centralized, searchable, and downloadable format to ensure broad accessibility. The bill targets agreements entered into on or after January 20, 2025, that include provisions such as reduced prices referencing foreign drug costs, expanded direct-to-consumer sales, import duty exemptions, or special treatment in demonstration projects like those from the Center for Medicare and Medicaid Innovation. It specifically lists 16 major drug manufacturers whose publicly announced agreements from late 2025 and early 2026 are subject to disclosure. While the bill prohibits withholding information due to reputational harm, it allows for the redaction of proprietary pricing information or data legally protected from disclosure, provided a written justification is published and submitted to Congress. Beyond disclosure, the bill mandates that the Secretary submit a report to Congress detailing all released and withheld documents, including the legal bases for any redactions. Furthermore, within 90 days of the initial disclosures, the Congressional Budget Office and the Government Accountability Office are required to jointly publish a report. This report must analyze the economic and budgetary effects of all disclosed agreements, including direct cost savings for individuals, impacts on Medicare and Medicaid, and effects on drug price competition and health plan formulary design.